MedTrace Logo

An Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia

NCT01504672 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 460

Last updated 2021-11-09

Study results available
· View outcomes & findings →

Summary

The aim of this randomized controlled study is to investigate if medication reviews performed by a clinical pharmacist as part of a ward team can reduce drug related problems and reduce readmissions to hospital among elderly patients (≥65 years) with dementia and cognitive failure.

Four hundred and sixty patients will be recruited and randomized to control (usual care) and intervention group (enhanced service in which a pharmacist is part of the health care team).

Six months after the last patient of the 460 has been discharged the study will be closed. Data about the number of readmissions and visits to the emergency room will be collected during the six-month follow-up and also, the costs associated with each visit or admission. Time until institutionalization will be compared between intervention group and control group.

Conditions

Interventions

OTHER

Medication review

In the intervention, the pharmacist will evaluate: * Is there an indication for the drug? * Has the drug desired effect? * Is the dose correct and dosing scheme correct? * Side effects, contraindications, inappropriate drugs * Interactions * Treatment time * Cost effectiveness * Adherence to recommendation list * Problems with handling the drugs (for example crushing of the tablets) * Untreated indication * Double medications * Administration of drugs

Sponsors & Collaborators

  • Umeå University

    lead OTHER

Principal Investigators

  • Hugo Lövheim, MD, PhD · Umeå University, Umeå, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2015-06-30
Completion
2015-08-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01504672 on ClinicalTrials.gov